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1. Introduction 
Infectious diseases are a global concern and the second commonest cause of death in the 
world. Of the annual 15 million deaths, 95% occur in the developing world, with 
predominance of acute respiratory infections, diarrhoeal diseases, measles, AIDS, malaria and 
tuberculosis (World Health Organization, 2008). More than 1 billion inhabitants in this part of 
the world do not have access to safe water and basic sanitation (Moe & Rheingans, 2006). 
Health care-associated infections (HCAIs) constitute an important health challenge 
worldwide and pose a major threat to patient safety. Risks for acquiring infections during 
health care delivery have increased dramatically with advances in diagnostic and treatment 
procedures. In developing world this challenge is more highlighted because infection 
prevention and control policies are either nonexistent, poorly adapted or insufficiently 
funded by governments (Ponce-de-Leon & Macias, 2003). Therefore, infections are between 
2-6 times higher than those in developed world. 
Hospitals are main facilities for the risk of acquiring an infection during the delivery of 
care. Therefore infection control and prevention activities are focused mainly at the 
hospital level. The rates of HCAIs within a hospital represent the best indicator for the 
quality of services offered, where a high frequency of HCAIs is evidence of a poor quality 
of health service delivery. But, nowadays their occurrence is increasing in outpatient 
clinics and in nursing homes as well.  
HCAIs impact on the population in many ways. They affect patients directly, causing 
increased morbidity and mortality; they may lead to disability and may reduce quality of 
life (Pittet et al., 2008). They also impact on the healthcare system by extending 
hospitalization of affected patients and driving up the costs of diagnosis and treatment. 
HCAIs may be transmitted from healthcare settings into the community. They also may be a 
subject of indictment by the treated patients in hospitals, decreasing the reputation of 
healthcare institutions in the eyes of the public. 
The endemic burden of HCAIs is significantly higher in developing countries, in particular 
in patients admitted to intensive care units and in neonates (Raka, 2008). Most developing 
countries lack surveillance systems for HCAI. They usually have limited and low quality 
data (Allegranzi et al., 2011). In developing world there are many determinants, which are 
specific to settings with limited resources described below. 
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2. Challenges of infection control in developing countries 
2.1 Health care and hospitals in developing world - Constraints and outcomes 
2.1.1 Resources and incomes  
Resources and incomes are unequally distributed throughout the world. Country economies 
are divided among income groups according to 2008 gross national income (GNI) per capita, 
calculated using the World Bank Atlas method. Countries with low income ( $975 or less) 
and lower middle income ( $976–3,855) are referred to as developing countries and they 
represent more than 75% of the world population. Prevention and control in low and middle 
income countries differs substantially from that in the developed world with high income. 
Limited resources represent the main challenge for governments in developing countries 
(Lynch et al., 2007). There may be a lack of commitment to healthcare by policy-makers in 
the developing world and allocation of funds is often disproportionate to the priorities set 
by providers. Priority in the allocation of funds is often directed to visible targets within 
society such as schools, infrastructure and security. Healthcare frequently is far behind. 
Even in countries where the healthcare budget is given high priority, the proportion 
devoted to prevention of HCAIs is usually insufficient.  
2.1.2 Health care system and society 
Health systems in developing countries are hospital-dominated, with 50-80% of resources 
allocated to hospitals in urban centres, which often have tertiary academic affiliations. On 
the other hand a large number of people present to the other regional hospitals, which have 
inadequate resources, staff training, and motivation with an impact on the health of millions 
of people (Duke et al., 2006). 
Corruption and nonformal payments are frequent in developing countries. Inadequate 
salaries lower the healthcare workers’ motivation for quality care. Information systems are 
not fully developed. There are limited grants available for research and no legislation 
mandating accreditation of hospitals and infection control programmes. In-service training 
for employees is highly variable and often minimal. Patients and their families may be 
required to provide care materials such as syringes, surgical gowns, and drugs. Frequent 
movement of patients and staff between hospitals wards results in an increased risk of 
transmission of multidrug-resistant microorganisms (Clements et al., 2008). Such 
transmission is often exacerbated by overcrowding, with patients sometimes sharing beds 
and supplies.  
During the last few decades, infection control activities in developing countries have 
increased, particularly in South America, South East Europe and countries of the former 
Soviet Union (Morris, 2008). Public pressure to improve the quality of hospital care, the 
increased cost of HCAIs in healthcare systems, the emergence of multiresistant 
microorganisms, the approach of occupational hazards have played an important role in this 
development. 
In many hospitals of developing countries adequate supplies to control and prevent 
infections are not available. Compliance with hand hygiene is often very low. Many other 
problems abound; for example, sterilisation departments are not centralised and there is 
lack of quality control in disinfection and sterilisation. Although many hospitals in the 
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developing countries may have infection control programmes and committees on paper, in 
practice they barely exist. Inadequate numbers of trained personnel work in infection 
control, and face continual resistance from clinical staff. This litany of problems means that 
the response to common outbreaks of disease in high risk units by management and staff is 
mainly reactive rather than proactive. Lack of ongoing surveillance results in delays in 
detecting outbreaks, with increasing costs and mortality. 
Baseline endemic infection rates are not established by the hospital authorities in vast 
majority of developing countries and usually there is no anticipation of the possible risks of 
acquiring a HCAI. Infection control does not exist as a medical or nursing speciality, and 
formal training programmes on infection control are not available in medical schools of 
developing world. In addition to mentioned constraints, frequent malnutrition and other 
types of infection and diseases contribute to increase the risk of HCAIs in developing 
countries. Poverty, war, economic and political disturbances all significantly increases 
HCAIs (Lynch et al., 2007). As a result of the weakness and problems outlined above, 
developing countries face the challenge of high rates of HCAIs and frequent outbreaks.  
2.2 Blood and injection safety 
Transfusion and injections may pose a risk for transmission of HIV and hepatitis in 
developing world. Between 5% and 10% of human immunodeficiency virus (HIV) infections 
worldwide are transmitted through transfusion of contaminated blood and blood products. 
Over 16 billion injections are administered each year in developing countries and the 
proportion of injections given by syringes and needles that are reused without sterilization 
ranges from 1.5 to 69.4% (Simonsen et al., 1999). Improper waste disposal is present in 18- 
64% of health care facilities of developing countries (World Health Organization, 2005). The 
2000 Global Burden of Disease study, death and disability from injection-associated 
infections by hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV revealed that 
patients received an average of 3.4 injections per year, 39.3% of which were given with 
reused equipment. Contaminated injections caused an estimated 21 million HBV infections, 
2 million HCV infections and 260 000 HIV infections, accounting for 32%, 40% and 5%, 
respectively, of new infections (Hauri et al., 2004).  
2.3 The burden and impact of health care-associated infections 
HCAIs represent one of the commonest adverse event during delivery of health care, 
complicating 5-10% of admissions to acute care hospitals in industrialised countries. Pooled 
prevalence of HCAI in Europe is 7.1% with range 3.5– 11.3% (ECDC, 2008). More than 4 
million patients are affected by HCAI every year in Europe and 1.7 million in USA. In 
developed countries, approximately 25-30% of patients admitted to Intensive Care Unit 
(ICU) are affected by HCAI. Urinary tract infections constitute a predominant portion of 
HCAIs with 30-40% of the overall infections. 
In developing countries the global picture of the burden of HCAI is unknown due to lack of 
reliable data and the use of different definitions and methodologies. Many developing 
countries have not conducted any surveillance studies regarding HCAIs and few studies 
provide information on etiology and risk factors for HCAIs (Allegranzi et al., 2011). Only 23 
developing countries of 147 (15.6%) reported a functioning HCAI national surveillance 
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system in 2010. Hospital-wide prevalence of HCAI in developing countries varied from 
5.7% to 19.1%. A review of several studies in developing world showed that increased 
length of stay associated with HCAI varied between 5 and 29.5 days. 
Surgical site infection (SSI) is the most surveyed and most frequent type of infection in 
developing countries with incidence rates ranging from 1.2 to 23.6 per 100 surgical 
procedures and a pooled incidence of 11.8%. By contrast, SSI rates vary between 1.2% and 
5.2% in developed countries (Allegranzi et al., 2011). Incidence of ICU-acquired infection is 
at least 2–3 fold higher than in high-income countries; device-associated infection densities 
up to 13 times higher than in the USA were reported in some studies. 
Ventilator-associated pneumonia (VAP) is a leading cause of death in hospitalised patients. 
A meta-analysis of articles concerning VAP in developing countries in MEDLINE (January 
1966 to April 2007) showed rates from 10 to 41.7 per 1000 ventilator-days; crude mortality 
ranged from 16% to 94% and with increased length of stay in intensive care (Arabi et al., 
2008). VAP attributable costs was US$ 10 000–25 000 per case. 
Many studies have shown the importance of HCAI among neonates in developing 
countries, where an average of 4384 children die every day of these infections (WHO, 2007). 
In a major review, reported rates of neonatal infections were 3-20 fold higher than those 
reported in industrialised countries (Zaidi et al., 2005). Neonatal infections are estimated to 
cause 1.6 million deaths annually, 40% of all neonatal deaths in developing countries (Lawn, 
2004). From microbiological prospective of HCAI in developing world the most frequent 
microbial pathogens were S. aureus in mixed patient populations, and Acinetobacter spp. in 
high-risk patients. 
The costs of HCAIs are substantial everywhere, although they varies between countries due 
to different health care systems. In countries with prospective payment systems based on 
diagnosis- related groups, hospitals lose from $583 to $4,886 for each HCAI. Annual 
economic impact of HCAIs in Europe is about 7 billion euro per year and 16 million extra-
days of hospital stay(ECDC, 2008). In the USA, associated costs are approximately US$ 6.5 
billion (Klevens et al., 2007). The cost to the government of Trinidad and Tobago for HCAIs 
was estimated at $697,000 annually. In Mexico, the annual cost approaches $1.5 billion; in 
Mexican ICUs, overall average cost of a HCAI episode was calculated at US$ 12 155 
(Higuera et al., 2007). In Thailand 10% of the annual hospital budget is spent on HCAIs 
(WHO, 2005). Some investigators have attempted to measure costs related to hospital 
outbreaks of HCAIs caused by multiresistant organisms. In a study of infections caused by 
MRSA it was estimated that average cost was $4000 per infection, whereas costs of C. 
difficile-associated diarrhea was approximately $4500 per patient (Stone, 2009). In an 
university hospital in Malaysia the cost of antibiotics prescribed to treat HCAI was 
estimated at US$ 521 000 per year (Hughes et al., 2005).  
2.4 Antimicrobial resistance 
Resistance to antimicrobial agents is a global challenge in all healthcare facilities. In 
developing countries inappropriate and uncontrolled use of antibiotics is very common 
and antimicrobials are frequently available over the counter in pharmacies. In many 
developing countries resistance among common pathogens to cheap antimicrobials has 
already increased drastically, resulting in limited effectiveness. The quality and potency 
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of antibiotics are often suspected, with unregulated import, registration and distribution. 
Another factor contributing to resistance is lack of antibiotic policies or basic 
recommendations at governmental level or within hospitals. Between 20% and 50% of a 
hospital budget is spent on antimicrobials, which are used to treat more than half of all 
patients. Even in developed countries >50% of antimicrobials are prescribed incorrectly, 
either administered in suboptimal doses or for incorrect duration (Wenzel, 2000). Misuse 
has been identified as an important factor in the emergence of antimicrobial resistance 
(Kollef, 2001). In turn, this resistance makes the clinical management of the patients more 
difficult. 
The use of antimicrobials in the veterinary area had an important impact on increase of 
antimicrobial resistance. Other factors contributing to increase of antimicrobial resistance 
are: limited number of new classes of antibiotics in pipeline by pharmaceutical companies 
and globalization, which enabled the rapid spread of multiresistant microorganisms 
worldwide (Okeke, 2005). 
 
Pooled mean (range) 
(interquantile range, 
25-75%) 
Pooled mean(range) 
(interquantile range,  
25-75%) 
Antibiotic resistant pathogen INICC 2002-2007 US NNIS 1992-2004 
Methicillin-resistant Staphylococcus 
aureus (MRSA) 
80.8 (50.0-100.0) 52.9 (32.7-603) 
Methicillin-resistant coagulase-negative 
staphylococci 
75.2 (64.0-100.0) 76.6 (69.4-83.8) 
Vancomycin-resistant enterococcus 
species 
9.4 (0.0-6.3) 13.9 (5-24.3) 
Ciprofloxacin/ofloxacin-resistant 
Pseudomonas aeruginosa 
52.4 (40.0-75.0) 34.8 (17.4-41.3) 
Imipenem-resistant P aeruginosa 36.6 (0.0-52.4) 19.1 (8.3-25.5) 
Ceftazidime-resistant P aeruginosa 51.7 (33.3-72.7) 13.9 (5-16.9) 
Piperacillin-resistant P aeruginosa 50.8 (36.4-75.0) 17.50 (7.5-19.5) 
Ceph3-resistant Enterobacter species 56.8 (30.8-80.0) 27.70 (17.4-36.4) 
Carbapenem-resistant Enterobacter 
species 
8.5 (0.0-0.0) 0.70 (0.0-0.0) 
Ceph3-resistant Klebsiella pneumoniae 68.2 (33.3-85.7) 6.20 (0.0-8.0) 
Ceph3-resistant Escherichia coli 53.9 (11.1-80.0) 1.3 (0.0-2.6) 
Ciprofloxacin/ofloxacin-resistant E coli 42.6 (12.7-78.9) 7.30 (0.0-8.2) 
Table 1. Comparison of antimicrobial resistance rates (%) in the ICUs of the International 
Nosocomial Infection Control Consortium (INICCC) and the U.S. National Nosocomial 
Surveillance System (NNIS) (Rosenthal et al., 2010). 
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Table 1 presents overview of antimicrobial reisistance rates in ICU between INICC and 
NNIS system. The frequencies of resistance of Staphylococcus aureus isolates to methicillin 
(MRSA) (80.8% vs 52.9%), Enterobacter species to ceftriaxone (50.8% vs 17.8%), and 
Pseudomonas aeruginosa to fluoroquinolones (52.4% vs 34.8%) were also far higher in the 
Consortium’s ICUs. 
2.5 Consequences 
As a result of the weakness and problems outlined above, developing countries face the 
challenge of high rates of HCAI and frequent hospital outbreaks. Another consequence of 
insufficient infection control infrastructure is the spread of multidrug-resistant organisms, 
such are meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 
Enterococcus spp. (VRE), extended-spectrum b-lactamase-producing Gram-negative bacilli, 
multidrug-resistant Mycobacterium tuberculosis and fluconazole-resistant Candida spp.  
3. Solutions and perspectives for prevention and control 
In order to improve the effectiveness of infection control in developing countries, a 
multifactorial initiatives needs to be implemented (Borg, 2010). Some of these initiatives are 
cheap and cost-effective, whereas others have a budget implications for governments. 
3.1 Prevention comes first 
Most countries address the problem of HCAI differently. As healthcare systems vary 
widely, so preventive strategies must be designed accordingly. The key component of 
solution is infection prevention. The prevention and control of HCAIs requires a triangle 
partnership between health care workers (HCW), government and community. Most HCAIs 
can be prevented with readily available and relatively inexpensive strategies. The Study on 
the Efficacy of Nosocomial Infection Control in 1974 showed that effective infection control 
programmes could reduce infection rates by as much as 32% and be cost-effective (Haley, 
1980). In an overview of published reports on the effect of infection control programmes 
from 1990 to 2002, Harbarth et al. found that between 10% and 70% of HCAIs were 
preventable (Harbarth, 2003). In the Hospital Sao Paulo in Brazil, there was a 71% decline in 
all HCAIs in the ICU when an infection control programme was implemented, saving about 
US $2 million (Cavalcante, 2001). Many other successful strategies have been documented. 
3.2 Political commitment and support 
In developing countries, the risk of patients and HCWs acquiring HCAIs could be 
significantly reduced if governments make infection control a high priority. Administrative 
controls are amongst the most important steps in prevention and control of HCAIs. 
Therefore a political support and commitment is essential in effectiveness of all other 
measures. National authorities must understand that without the proper resources, 
hospitals can be high risk areas. Therefore health care authorities must establish and 
support a comprehensive, effective national programme. Such a programme should set 
national objectives, and develop strategies, guidelines and policies for specific infection 
control issues, which are regularly updated. Many countries already have such 
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programmes. If these programmes are not available, those from the developed world should 
be adopted. Since developing countries have their own characteristic problems, these must 
be taken into account when formulating recommendations and policies (Raza et al.,2004). 
Due to their contact with patients or infected material from patients, many health care 
workers are at risk for exposure and possible transmission of infectious agents. Therefore 
occupational health and immunisation of HCWs is an essential part of prevention and 
infection control programmes (Randle, 2006). Moreover, education of HCWs and 
behavioural models complete the mosaic for prevention and control of HCAIs. 
3.3 Hand hygiene 
Hand hygiene remains the simplest and the primary measure to prevent HCAI and reduce 
spread of multidrug resistant organisms. Although hand hygiene is a simple measure, the 
lack of compliance among healthcare workers is problematic worldwide, averaging <40% 
(Boyce & Pittet 2002). In 2002, the CDC recommended the use of alcoholic hand rubs which 
have the advantage that they can be placed at the bedside (Hugonet et al., 2003). Also, where 
hand-washing facilities are primitive or scarce, it is often easier to provide a hand rub than 
sinks with running water and a functioning sewage system. Introduction of alcohol- based 
hand rub has led to increased hand hygiene compliance among healthcare workers and 
fewer HCAIs (Rosenthal et al., 2005). Today, many developing countries use WHO based 
formulation for alcoholic hand rub. In some developing countries, implementation of 
education, process surveillance, and performance feedback has considerably enhanced hand 
hygiene compliance (Damani, 2008).  
3.4 Surveillance 
Surveillance is an essential component in HCAIs prevention, with the aims of outbreak 
identification, establishment of endemic baseline rates of infection and the evaluation of 
control measures. Surveillance data can be used to identify preventable infections in high 
risk areas, so that resources are targeted to high priority areas. Surveillance of most 
important HCAIs should be accompanied by surveillance of antimicrobial use and 
resistance pattern. There is good evidence that antibiotic stewardship programmes have 
been successful in modifying antimicrobial prescribing practices, resulting in most instances 
in reduction of use (Gould, 1999). Unfortunately, such programmes are often lacking in 
developing countries, and antimicrobial resistance problems emphasise the importance of 
clinical microbiology laboratory services (Pfaller & Herwalt, 1997). 
3.5 The bundle approach 
In order to meet the required level of prevention, multiple strategies must be implemented 
simultaneously. Care bundles are part of a set of multiple intervention strategies to improve 
patient outcomes. They have been introduced in the USA by Institute for Healthcare 
Improvement and through the Saving Lives initiative produced by the UK Department of 
Health as hight impact interventions. Bundles are directed generally at aseptic procedures 
that carry a high risk of HCAI if not done properly (Westwell, 2008). These usually represent 
a set of three to five practices that, when performed collectively, reliably, and continuously 
have been proven to improve patient outcomes. Bundles also incorporate a simple audit tool 
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to check that they are being implemented. The bundles are focused on the most important 
HCAIs: catheter-associated bloodstream infection, catheter-associated UTI, ventilator-
associated pneumonia and SSI.  
Bundled interventions using systems quality improvement approaches for improved 
infection control in developing countries face many obstacles. Limited resources, poor 
infrastructure, insufficient equipment, lack of national guidelines, policies and evidence are 
key difficulties in successful implementation of bundle approach. 
3.6 Global initiatives: World alliance for patient safety  
Improving the safety of patient care is now a global issue. A growing awareness of HCAIs 
and patient safety prompted the World Health Organization (WHO) to promote the creation 
of the World Alliance for Patient Safety to coordinate, spread and accelerate improvements 
in patient safety (Allegranzi et al., 2007). Prevention of HCAI is the target of the Alliance’s 
First Global Patient Safety Challenge, ‘Clean Care is Safer Care’, launched in October 2005. 
Implementation strategies include the integration of multiple interventions in the areas of 
blood safety, injection safety, clinical procedure safety, and water, sanitation and waste 
management, with the promotion of hand hygiene in healthcare as the cornerstone. The 
main target of the campaign is 'Five Moments for Hand Hygiene' approach. It defines the 
key moments for hand hygiene with united vision. Various tools and resources have been 
developed to complement the Five Moments approach including localized country specific 
tool (Allegranzi & Pittet, 2009). 
3.7 Research 
One measure to improve the knowledge base of infection control is through research and 
development. Research resources for addressing infection control problems of developing 
countries remain disproportionately low compared with the disease burdens borne by these 
countries. National economies in developing countries remains too weak to support 
research and development. Research activities are sporadic and marginal, based mainly on 
individual initiatives in the university sector and with almost no support from governments. 
There is a need to focus these limited resources on research that will optimize health benefits 
with cost-effective interventions. Research priorities of developing countries in the field of 
HCAI are different compared to developed world. Research infrastructure should be 
focused on evaluating costs of HCAIs, risk factors for developing HCAI, hand hygiene, 
gather surveillance data on HCAI, study on antibiotic consumption and resistance 
patterns and monitor impact of infection control programmes. Publications from 
developing countries are increasing daily. An important window for research in 
developing countries arose through the International Nosocomial Infection Control 
Consortium (INICC). The INICC is the first multinational research network established to 
control HCAIs in hospitals in limited-resource countries. It has developed from South 
American hospitals in 1998 to a dynamic network of 450 healthcare centers in 108 cities, 
from 36 countries of 4 continents. It is the only source of aggregate standardized 
international data on HCAIs epidemiology in intensive care. 
INICC published a surveillance study from January 2003 through December 2008 in 173 
ICUs in Latin America, Asia, Africa, and Europe. During the 6- year study, using CDC 
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NNIS/NHSN definitions for device-associated healthcare-associated infection, 
prospective data were collected from 313,008 patients hospitalized in the consortium’s 
hospital ICUs for an aggregate of 2,194,897 days (Rosenthal et al., 2011). Despite the fact 
that the use of devices in the developing countries' ICUs was remarkably similar to that 
reported in US ICUs in the CDC's NHSN, rates of device-associated nosocomial infection 
were significantly higher in the ICUs of the INICC hospitals; the pooled rate of central line-
associated bloodstream infection in the INICC ICUs of 6.8 per 1,000 central line-days was 
more than 3-fold higher than the 2.0 per 1,000 central line-days reported in comparable US 
ICUs. The overall rate of ventilator-associated pneumonia also was far higher (15.8 vs 3.3 
per 1,000 ventilator-days), as was the rate of catheter-associated urinary tract infection (6.3 
vs. 3.3 per 1,000 catheter-days) and the crude unadjusted excess mortalities of device-related 
infections ranged from 7.3% (for catheter-associated urinary tract infection) to 15.2% (for 
ventilator-associated pneumonia). 
 
INICC 
2004–2009 
Pooled Mean (95% CI) 
U.S. NHSN 
2006-2008 
Pooled Mean (95% CI) 
Medical Cardiac ICU 
CLAB 6.2 (5.6 – 6.9) 2.0 (1.8 – 2.1) 
CAUTI 3.7 (3.2 – 4.3) 4.8 (4.6 – 5.1) 
VAP 10.8 (9.5 – 12.3) 2.1 (1.9 – 2.3) 
   
Medical-surgical ICU 
CLAB 6.8 (6.6 – 7.1) 1.5 (1.4 – 1.6) 
CAUTI 7.1 (6.9 – 7.4) 3.1 (3.0 – 3.3) 
VAP 18.4 (17.9 – 18.8) 1.9 (1.8 – 2.1) 
   
Pediatric ICU 
CLAB 4.6 (3.7 – 5.6) 3.0 (2.7 – 3.1) 
CAUTI 4.7 (4.1 – 5.5) 4.2 (3.8 – 4.7) 
VAP 6.5 (5.9 – 7.1) 1.8 (1.6 – 2.1) 
   
Newborn ICU (1501-2500 g) 
CLAB  11.9 (10.2 – 13.9) 1.5 (1.2 – 1.9) 
VAP 10.1 (7.9 – 12.8) 0.8 (0.04 – 1.5) 
   
CI, confidence interval; ICU, intensive care unit; DA-HAI, device associated health care associated 
infection; INICC, International Nosocomial Infection Control Consortium; NHSN, National Healthcare 
Safety Network; CAUTI, catheter-associated urinary tract infections; CLAB, central line-associated 
blood stream infection; VAP, ventilator-associated pneumonia. 
Table 2. Device associated infections (DAI) rates (per 1000 device-days) in the ICUs of the 
low income countries participating in International Nosocomial Infection Control 
Consortium (INICC) and the U.S. National Healthcare Safety Network(NHSN)(Rosenthal 
et al., 2011). 
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3.8 Environment 
Isolation precautions with disinfection and sterilization comprise another important brick in 
the wall of infection control. Isolation precautions are important step in preventing 
transmission of infectious agents within the hospital wards. Isolation systems enable health 
care workers to identify patients who need to be isolated and undertake appropriate 
precautions. In developing world there is a lack of isolation rooms and usually patients with 
infections caused by same microorganisms are cohorted in same rooms. Personal protective 
equipment support achievement of this objective. Education of healthcare workers 
regarding standard precautions and safe and appropriate use of injections are important for 
prevention and control of HCAI. Important steps in prevention of HCAI are introduction of 
validated processes for decontamination, cleaning and sterilisation or high level disinfection 
of soiled instruments and other items; and improving safety in operating rooms and other 
high risk areas (Rutala & Webber, 2004). 
3.9 Infection control societies 
Many countries have not yet established infection control societies or associations, and 
general professional societies of physicians, nurses, and laboratory staff are not effectively 
engaged in infection control and prevention activities. The International Federation of 
Infection Control (IFIC) is an umbrella organisation of societies and associations of 
healthcare professionals in infection control and related fields worldwide including majority 
of them coming from developing countries. Currently IFIC has 66 members from 51 
countries, and provides guidelines and educational material. Many regional and 
international networks throughout the world also participate in IFIC.  
3.10 Microbiology laboratory support for infection control  
Clinical microbiology laboratory plays a pivotal role in patient care providing information 
on a variety of microorganisms with clinical significance and is an essential component of an 
effective infection control program (Kalenic & Budimir, 2009). Laboratory plays important 
duties in prevention of HCAIs, which include: surveillance of HCAIs and antimicrobial 
resistance, rapid communication of laboratory data relevant to infection control, 
epidemiology typing of isolated pathogens, storing laboratory data and isolates, outbreak 
investigation and management. A variety of methods can be used to identify 
microorganisms in clinical specimens, although in developing countries diagnostic 
capabilities are insufficient. Partnership between the infection preventionist and the clinical 
microbiology laboratory staff is crucial in combating against HCAIs.  
3.11 Combating antibiotic resistance 
There is good evidence that antibiotic stewardship programmes have been successful in 
modifying antimicrobial prescribing practices, resulting in most instances in reduction of 
use. Unfortunately, such programmes are often lacking in developing countries, and 
antimicrobial resistance problems emphasise the importance of clinical microbiology 
laboratory services(Sosa et al.,2010) . Key actions in prevention and control of antimicrobial 
resistance are: empower the surveillance systems of antibiotic use and antibiotic resistance, 
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prudent use in clinical practice (governmental measures, increase awareness of the public 
and health care workers, upgrading diagnostic capabilities), prudent use in veterinary, 
infection control in hospitals and community, implementation of Information technology, 
applied research and international cooperation. 
4. Conclusion 
HCAIs represent a major threat to patient safety and quality healthcare in developing 
countries. In many hospitals of developing world infection control activities are limited by 
many constraints in all levels of health care. As a consequence, these countries are facing the 
challenges of higher rates of hospital infections, frequent outbreaks, unsafe care and spread 
of infections in acute care facilities and community. The best solution for this challenge 
entail a multifactorial initiatives, which have to be sustainable in order to have a great 
impact on outcomes. Through focusing on infection control, countries with limited resources 
can improve the quality of healthcare in the future. 
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